Business & Technology News » Blog Archive » EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

19 Jul 2021

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Author: admintech | Filed under: Press Release

CHARLESTON, S.C. and COPENHAGEN, Denmark, July 19, 2021 /PRNewswire/ — EPI Health and MC2 Therapeutics, announced today commercial availability in the United States of Wynzora® Cream (calcipotriene and betamethasone dipropionate, w/w 0.005%/0.064%) for the topical treatment of plaque…

This entry was posted on Monday, July 19th, 2021 at 7:11 am and is filed under Press Release. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed.

EPI Health and MC2 Therapeutics announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (calcipotriene and betamethasone dipropionate w/w 0.005%/0.064%)

Categories